Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?Investors Business Daily • 08/27/26
AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?Seeking Alpha • 08/19/26
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely SuccessZacks Investment Research • 08/18/26
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSOBusiness Wire • 08/17/26
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?The Motley Fool • 08/14/26
Do Options Traders Know Something About AstraZeneca Stock We Don't?Zacks Investment Research • 08/11/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZNPRNewsWire • 08/07/26
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology TherapiesPRNewsWire • 08/04/26
More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or NotBarrons • 08/04/26
Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”24/7 Wall Street • 08/03/26
AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in FocusBenzinga • 08/03/26